Actionable news
0
All posts from Actionable news
Actionable news in ALXN: Alexion Pharmaceuticals, Inc.,

Celgene CELG slides on earnings; NEOS spikes on buyout offer

Price and Volume Movers

Celgene Corporation (NASDAQ:CELG) shares tumbled to close down 16% to $99.99 following its release of 3Q earnings. Although third quarter revenue was up on the previous year, long-term guidance through to 2020 was much lower than forecast, prompting concern among investors. For 2020, Celgene has forecast sales of $19b to $20b, compared with earlier guidance of over $21b. Current year guidance is for sales of approximately $13b compared with previous guidance of between $13 and $13.4b, with a slowdown in sales of Otezla among the reasons for the pullback.

Neos Therapeutics, Inc. (Nasdaq: NEOS) spiked in the morning session, closing up 38% to $10.05 following news that it has received an offer from PDL BioPharma, Inc. (NASDAQ: PDLI) to acquire all of the outstanding shares of Neos for $10.25 per share in cash.

AbbVie (NYSE: ABBV) announced positive top-line results from its three pivotal Phase 3 trials evaluating risankizumab compared to ustekinumab and adalimumab for the treatment of patients with moderate to severe chronic plaque psoriasis. Results of the trials showed that risankizumab achieved significantly greater response of clear or almost clear skin (sPGA 0/1) compared to STELARA (ustekinumab) and HUMIRA (adalimumab) with rates ranging from 84 to 88 percent at week 16. At one year, 56 and 60% of risankizumab patients achieved complete skin clearance (PASI 100) compared to STELARA (21 and 30%).

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares tumbled to close down 27% to $1.47 following the pricing of its underwritten public offering of 33.3m shares of its common stock at a public offering price of $1.50 per share for net proceeds of $46.8m.

Insys Therapeutics Inc (NASDAQ:INSY) shares slid 23% to $5.74 after its CEO, John Kapoor, was arrested on fraud charges relating to bribing doctors to prescribe its cancer pain drug, Subsys.

Other major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume INCLUDING sub-$1 stocks.

ADVANCERS:

Achieve Life Sciences Inc (NASDAQ:ACHV): $2.18; +15%.

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP): $2.18; +12%.

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN): $2.04; +11%.

Benitec Biopharma Ltd (ADR) (NASDAQ:BNTC): $2.74; +11%.

Alkermes Plc (NASDAQ:ALKS): $54.97; +11%.

DECLINERS:

Molecular Templates Inc (NASDAQ:MTEM): $7.13; -17%.

Moleculin Biotech Inc (NASDAQ:MBRX): $1.52; -17%.

Cidara Therapeutics Inc (NASDAQ:CDTX): $7.85; -10%.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): $14.10; -10%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst

ABBV
Risankizumab
Psoriasis

Phase 3 Phase 3 data released October 26, 2017 - primary endpoints met.

AKAO
Plazomicin
Complicated urinary tract infections (cUTI)

NDA Filing Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing announced October 26, 2017.

ALXN
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)

Phase 3 Phase 3 enrollment to be completed in 2017 with data due mid-2018.

ALXN
ALXN1210
atypical Hemolytic Uremic Syndrome (aHUS)

Phase 3 Phase 3 enrollment to be completed early 2018; Phase 3 trial in pediatric patients has also been initiated.

ALXN
ALXN1210
Paroxysmal nocturnal hemoglobinuria (PNH)

Phase 3 Phase 3 data due 2Q 2018.

ARGX
ARGX-110
Relapsed/refractory cutaneous T-cell lymphoma (CTCL)

Phase 2 Phase 2 interim data due by ASH 2017 with top-line data due by the end of 2018.

ARGX
ARGX-110
Acute myeloid leukemia (AML)

Phase 1/2 Phase 1/2 interim data due by ASH 2017.

ARGX
ARGX-113
Myasthenia gravis (MG)

Phase 2 Phase 2 data due 1Q 2018.

ARGX
ARGX-113
Immune thrombocytopenia (ITP)

Phase 2 Phase 2 data due 2H 2018.

ARGS
ARGX-113
Pemphigus vulgaris (PV)

Phase 2 Phase 2 initiation announced September 26, 2017 with interim data due 2H 2018.

HRTX
HTX-011
Bunionectomy and hernia repair

Phase 2 Phase 3 top-line data due 1H 2018.

NVCR
Tumor Treating Fields (TTFields) STELLAR
Mesothelioma

Phase 2 Phase 2 enrollment completion announced March 31, 2017. Data due 2018.

NVCR
Tumor Treating Fields (TTFields) - PANOVA
Pancreatic cancer

Phase 3 Phase 3 trial to be initiated 4Q 2017.

NVCR
Tumor Treating Fields (TTFields) - INNOVATE
Ovarian cancer

Phase 2 Phase 2 data presented December 12, 2016. Further promising PFS data released March 31, 2017. Phase 3 trial to be initiated in 2018.

NVCR
Tumor Treating Fields (TTFields) METIS
Brain Metastases Originating from Non-Small Cell Lung Cancer

Phase 3 Phase 3 enrollment commenced October 2016. Data due 2020.

NVCR
Tumor Treating Fields (TTFields) LUNAR
Non-small cell lung cancer (NSCLC)

Phase 3 Phase 3 commencement of enrollment announced February 15, 2017. Data due 2021.

TSRO
Rolapitant - intravenous (IV)
Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients

Approved CRL January 11 2017. FDA Approval announced October 25, 2017 following resubmission.

VTGN
AV-101
Adjunctive Treatment Major Depressive Disorder

Phase 2 Phase 2 trial to commence 1Q 2018 with completion due 2H 2018.

More